In Vitro and In Vivo Antimicrobial Activities of Vancomycinand Rifampin against Elizabethkingia anophelis

Meiho University Institutional Repository > 健康暨護理學院 > 資訊科技系 > 研究計畫 > Item 987654321/4206

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.meiho.edu.tw/ir/handle/987654321/4206

题名:	In Vitro and In Vivo Antimicrobial Activities of Vancomycinand Rifampin against Elizabethkingia anophelis
作者:	I-Fan, Lin 1;Lai, Chung-Hsu;Lin, Shang-Yi;Lee, Ching-Chi;Lee, Nan-Yao;Liu, Po-Yu;Yang, Chih-Hui;Huang, Yi-Han;Lin, and Jiun-Nong
贡献者:	健康科學管理學院
日期:	2024-03-29
上传时间:	2024-03-29T06:34:13Z (UTC)
摘要:	Elizabethkingia anophelis has emerged as a critical human pathogen, and a number of isolated reports have described the successful treatment of Elizabethkingia infections with vancomycin, a drug that is typically used to target Gram-positive bacteria. This study employed in vitro broth microdilution checkerboard and time-kill assays, as well as in vivo zebrafish animal models to evaluate the individual and combination antimicrobial effects of vancomycin and rifampin against E. anophelis. The minimum inhibitory concentration ranges of vancomycin and rifampin against 167 isolates of E. anophelis were 16–256 mg/L and 0.06–128 mg/L, respectively. The checkerboard assay results revealed a synergistic effect between vancomycin and rifampin in 16.8% (28/167) of the isolates. Time-kill assays were implemented for 66 isolates, and the two-drug combination had a synergistic interaction in 57 (86.4%) isolates. In vivo zebrafish studies revealed that treatment with vancomycin monotherapy, rifampin monotherapy, or vancomycin–rifampin combination therapy yielded a higher survival rate than the control group treatment with 0.9% saline. The results of this study support the use of vancomycin to treat E. anophelis infections.
显示于类别:	[資訊科技系] 研究計畫

文件中的档案:

档案	描述	大小	格式	浏览次数
In Vitro 2024-全文.pdf		1345Kb	Adobe PDF	0	检视/开启

检视Licence

在MUIR中所有的数据项都受到原著作权保护.

数据加载中.....